A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC -X Trial).

被引：11

作者：

Gonzalez, Maria

Hong, Angela M.

Carlino, Matteo S.

Atkinson, Victoria

Wang, Wei

Lo, Serigne

Brown, Michael Paul

Foote, Matthew C.

Pinkham, Mark B.

Le, Hien

Roos, Daniel E.

Osorio, Monica

Haghighi, Neda

Kok, David

Postow, Michael A.

McArthur, Grant A.

Menzies, Alexander M.

Long, Georgina V.

机构：

[1] Melanoma Inst Australia, Sydney, NSW, Australia

[2] Univ Sydney, Chris OBrien Lifehouse, Melanoma Inst Australia, Sydney, NSW, Australia

[3] Univ Sydney, Westmead Hosp, Sydney, NSW, Australia

[4] Univ Sydney, Blacktown Hosp, Melanoma Inst Australia, Sydney, NSW, Australia

[5] Univ Queensland, Gallipoli Med Res Fdn, Princess Alexandra Hosp, Woolloongabba, Qld, Australia

[6] Westmead Hosp, Crown Princess Mary Canc Ctr, Sydney, NSW, Australia

[7] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia

[8] Royal Adelaide Hosp, Adelaide, SA, Australia

[9] Univ Queensland, Princess Alexandra Hosp, Brisbane, Qld, Australia

[10] Univ Queensland, Queensland Univ Technol, Gamma Knife Ctr Queensland, Princess Alexandra Hosp, Woolloongabba, Qld, Australia

[11] Univ Adelaide, Royal Adelaide Hosp, Adelaide, SA, Australia

[12] Melanoma Inst Australia, Sydney, NSW, Australia

[13] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[15] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[16] Univ Sydney, Melanoma Inst Australia, Royal North Shore Hosp, Sydney, NSW, Australia

[17] Royal North Shore Hosp, Sydney, NSW, Australia

[18] Mater Hosp, Sydney, NSW, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.TPS9600

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS9600

引用

页数：2

共 50 条

[1] Nivolumab plus ipilimumab in melanoma brain metastases
Giacomo, Anna Maria Di
Maio, Michele
LANCET ONCOLOGY, 2022, 23 (02): : E53 - E53
[2] Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery
Tang, Joseph D.
Mills, Matthew N.
Nakashima, Justyn
Dohm, Ammoren E.
Khushalani, Nikhil I.
Forsyth, Peter A.
Vogelbaum, Michael A.
Wuthrick, Evan J.
Yu, Hsiang-Hsuan M.
Oliver, Daniel E.
Liu, James K. C.
Ahmed, Kamran A.
JOURNAL OF NEURO-ONCOLOGY, 2024, 166 (03) : 431 - 440
[3] Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery
Joseph D. Tang
Matthew N. Mills
Justyn Nakashima
Ammoren E. Dohm
Nikhil I. Khushalani
Peter A. Forsyth
Michael A. Vogelbaum
Evan J. Wuthrick
Hsiang-Hsuan M. Yu
Daniel E. Oliver
James K. C. Liu
Kamran A. Ahmed
Journal of Neuro-Oncology, 2024, 166 : 431 - 440
[4] CLINICAL OUTCOMES OF MELANOMA BRAIN METASTASES TREATED WITH NIVOLUMAB AND IPILIMUMAB ALONE VERSUS NIVOLUMAB AND IPILIMUMAB WITH STEREOTACTIC RADIOSURGERY
Tang, Joseph
Mills, Matthew
Dohm, Ammoren
Khushalani, Nikhil
Forsyth, Peter
Vogelbaum, Michael A.
Wuthrick, Evan
Yu, Hsiang-Hsuan Michael
Oliver, Daniel
Liu, James
Ahmed, Kamran
NEURO-ONCOLOGY, 2023, 25
[5] 009 Randomized, open -label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
Kaseb, A.
Vence, L.
Blonde, J.
Yadav, S.
Pestana, R.
Vauthey, J.
Cao, H.
Chun, Y.
Sakamura, D.
Wolff, R.
Yoe, J.
Allison, J.
Sharma, P.
ANNALS OF ONCOLOGY, 2019, 30
[6] Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
Kaseb, A.
Duda, D. G.
Cao, H. S. Tran
Abugabal, Y. I.
Vence, L. M.
Rashid, A.
Pestana, R. Carmagnani
Blando, J. M.
Singh, S.
Vauthey, J. N.
Chun, Y. S.
Tzeng, C-W. D.
Sakamuri, D.
Wolff, R. A.
Yao, J. C.
Allison, J.
Sharma, P.
ANNALS OF ONCOLOGY, 2019, 30 : 880 - 880
[7] Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
Kaseb, Ahmed Omar
Pestana, Roberto Carmagnani
Vence, Luis M.
Blando, Jorge M.
Singh, Shalini
Ikoma, Naruhiko
Vauthey, Jean-Nicolas
Allison, James Patrick
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
[8] Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC
Omar Kaseb, Ahmed
Duda, Dan G.
Tran Cao, Hop Sanderson
Abugabal, Yehia I.
Vence, Luis M.
Rashid, Asif
Pestana, Roberto
Blando, Jorge M.
Singh, Shalini
Vauthey, Jean-Nicolas
Hassan, Manal
Amin, Hesham M.
Qayyum, Aliya
Shin Chun, Yun
David Tzeng, Ching-Wei
Sakamuri, Divya
Wolff, Robert A.
Yao, James C.
Patrick Allison, James
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[9] Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Wolchok, Jedd D.
Chiarion-Sileni, Vanna
Gonzalez, Rene
Grob, Jean-Jacques
Rutkowski, Piotr
Lao, Christopher D.
Cowey, C. Lance
Schadendorf, Dirk
Wagstaff, John
Dummer, Reinhard
Ferrucci, Pier Francesco
Smylie, Michael
Butler, Marcus O.
Hill, Andrew
Marquez-Rodas, Ivan
Haanen, John B. A. G.
Guidoboni, Massimo
Maio, Michele
Schoffski, Patrick
Carlino, Matteo S.
Lebbe, Celeste
McArthur, Grant
Ascierto, Paolo A.
Daniels, Gregory A.
Long, Georgina, V
Bas, Tuba
Ritchings, Corey
Larkin, James
Hodi, F. Stephen
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 127 - +
[10] Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
Kaseb, Ahmed Omar
Pestana, Roberto Carmagnani
Vence, Luis M.
Blando, Jorge M.
Singh, Shalini
Ikoma, Naruhiko
Vauthey, Jean-Nicolas
Allison, James Patrick
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)

← 1 2 3 4 5 →